Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial-Reference-Cited by-同舟云学术

Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial

Published:2001-01 Issue:1 Volume:2 Page:27-34
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:

Author:

Katlama C,Clotet B,Plettenberg A,Jost J,Arasteh K,Bernasconi E,Jeantils V,Cutrell A,Stone C,Purdon S,

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1468-1293.2001.00043.x/fullpdf

Reference13 articles.

1. Intensifying antiretroviral therapy: why, when and how;Kuritzkes;HIV,1999

2. Fischl , M Greenberg , S Clumeck , N et al. Ziagen (Abacavir, ABC, 1592) combined with 3TC and ZDV is highly effective and durable through 48 weeks in HIV-1 infected antiretroviral-therapy-naive subjects (CNA3003) 6th Conference on Retroviruses and Opportunistic Infections. 31 January

3. Rozenbaum , W Katlama , C Massip , P Lanier , R Mamet , JP David , F. 8 weeks results (CNA3009) 7th European Conference on Clinical Aspects and Treatment of HIV Infection. 2327 October, 1999

4. Lange , J Ait-Khaled , M De Wolf , F Foudraine , N Maguire , M. Does the M184V mutation affect the efficacy of HAART? 7th European Conference on Clinical Aspects and Treatment of HIV Infection. 2327 October, 1999

5. The presence of the M184V mutation is not sufficient to diminish response to ABC/3TC/ZDV in therapy experienced children (CNA3006);Danehower;Antiviral Res,1999

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen;HIV Clinical Trials;2010-12

2. A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1–Infected Patients: 48-Week Results of the SHIELD Trial;HIV Clinical Trials;2010-10

3. Successful implementation of a national HLA-B*5701 genetic testing service in Canada;Tissue Antigens;2010-01

4. Intensification of a suppressive HAART regimen increases CD4 counts and decreases CD8+ T-cell activation;Clinical Immunology;2008-03

5. Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial;HIV Medicine;2007-04